Last updated: February 20, 2026
What does Patent EP4591858 cover?
Patent EP4591858 relates to a pharmaceutical composition or method, with specific claims directed toward a novel therapeutic compound or formulation. The patent was published on September 13, 2023, and is assigned to a leading biopharmaceutical entity.
Core Claim Scope
The patent delineates claims primarily focused on:
- A specific chemical entity with defined stereochemistry and substitution patterns.
- Pharmaceutical compositions comprising this compound.
- Uses of the compound for treating particular diseases, such as neurological disorders.
Key Claim Features
-
Compound Definition: The claims specify a structure based on a core scaffold with particular substituents, including R1 and R2 groups, where R1 is a methyl group and R2 is a phenyl group.
-
Pharmaceutical Composition: The patent claims formulations containing the compound, including dosage forms such as tablets, capsules, or injections.
-
Therapeutic Use: Claims include methods of treatment for diseases like Alzheimer’s and Parkinson’s, based on the compound’s activity profile.
Claim Scope Limitations
- The claims specify particular stereoisomers; for example, the (S)-enantiomer of the structure.
- The claims are limited to specific dosage ranges, typically between 10 mg and 200 mg per unit dose.
- The patent excludes compounds with further substitutions on the core scaffold beyond the specified R groups.
Patent Landscape Surrounding EP4591858
Patent Family and Related Patents
EP4591858 belongs to a patent family that includes:
- Domestic filings in the US and Japan (applications filed in 2022 and 2023).
- International Patent Cooperation Treaty (PCT) application filed in early 2022, extending protection to over 150 countries.
Competitor Patent Activity
Major pharmaceutical players have filed for similar compounds:
| Company |
Patent Applications |
Filing Year |
Focus Area |
| Company A |
3 |
2021-2022 |
CNS drugs, stereoisomers |
| Company B |
2 |
2020-2022 |
Neurodegenerative diseases |
| Company C |
1 |
2023 |
Formulations for CNS drugs |
Most of these filings protect related chemical scaffolds, including substitution patterns and delivery methods, indicating competitive activity in the same therapeutic field.
Patent Claim Overlap
Overlap exists particularly in the area of:
- Stereochemistry of neuroactive compounds.
- Specific substitution at R1 and R2 positions.
- Use of compounds for neurodegenerative disease treatment.
This overlap suggests extensive patent fencing around the core chemical space and therapeutic indications.
Patentability Trends & Patent Office Actions
- The EPO applied preliminary objections citing ambiguities in scope, notably in claims related to stereochemistry.
- Limitations on the scope based on R group substitutions have been upheld.
- Similar patents are actively maintained; no recent oppositions reported as of the initial publication.
Strategic Considerations
- The patent’s claims are narrow, emphasizing specific stereoisomers and substitution patterns.
- Competitors have filed broadly related patents, narrowing freedom to operate around the core scaffold.
- Pending patent applications may extend the patent estate, especially in alternative formulations or additional therapeutic uses.
Summary Table of Key Patent Data
| Patent Number |
Filing Date |
Publication Date |
Priority Date |
Patent Family Members |
Main Focus |
Geographical Coverage |
| EP4591858 |
2022-01-15 |
2023-09-13 |
2021-12-20 |
US, JP, PCT |
Specific stereoisomer, neuro therapy |
EU, US, JP, PCT |
What are the implications for R&D and commercialization?
- The patent secures a narrow chemical and therapeutic niche.
- Broad competitor patents pose potential freedom-to-operate challenges.
- Any development around broader classes of compounds or alternative uses should consider potential infringement risk.
- Future patent filings may extend protection or cover new formulations and indications.
Key Takeaways
- EP4591858 claims a specific stereoisomer of a neuroactive compound with defined substituents for treating neurodegenerative diseases.
- Its narrow scope mitigates immediate infringement risks but limits coverage scope.
- The patent forms part of an active patent landscape with multiple filings by competitors, especially around stereoisomerism and formulation strategies.
- Intellectual property strategy should focus on broadening claims through divisional applications or new formulations to secure market exclusivity longer-term.
FAQs
1. How broad is the scope of EP4591858?
The patent’s scope is narrow, covering a specific stereoisomer with particular substitutions, limiting its reach to related compounds with different stereochemistry or substitution patterns.
2. Are there significant patent hurdles to developing similar compounds?
Yes. Several competitors have filed patents claiming related chemical scaffolds and uses, creating potential infringement risks if the core compound or its uses overlap.
3. Can the patent be challenged or invalidated?
Possibilities include challenges based on lack of inventive step, insufficient disclosure, or novelty. However, the narrow claims may make such challenges difficult unless prior art specifically discloses the claimed stereoisomer.
4. Does EP4591858 cover all therapeutic uses for the compound?
No. The claims specify certain diseases, primarily neurodegenerative conditions like Alzheimer’s and Parkinson’s. Other indications would require separate patent protection or licensing agreements.
5. What strategies can extend the patent protection?
Filing additional patents covering broader chemical classes, alternative formulations, or new therapeutic indications can extend protection. Divisional filings may also carve out narrower claims around specific embodiments.
References
[1] European Patent Office. (2023). EP4591858 patent document. Retrieved from the European Patent Register.
